JP2013517331A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517331A5 JP2013517331A5 JP2012550126A JP2012550126A JP2013517331A5 JP 2013517331 A5 JP2013517331 A5 JP 2013517331A5 JP 2012550126 A JP2012550126 A JP 2012550126A JP 2012550126 A JP2012550126 A JP 2012550126A JP 2013517331 A5 JP2013517331 A5 JP 2013517331A5
- Authority
- JP
- Japan
- Prior art keywords
- ilt5
- antibody
- cell
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 73
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 70
- 239000012634 fragment Substances 0.000 claims description 61
- 239000000427 antigen Substances 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 claims description 48
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 claims description 48
- 230000001939 inductive effect Effects 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 230000003013 cytotoxicity Effects 0.000 claims description 9
- 231100000135 cytotoxicity Toxicity 0.000 claims description 9
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 108091008874 T cell receptors Proteins 0.000 claims description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 7
- 239000012645 endogenous antigen Substances 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 230000009696 proliferative response Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 3
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 3
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 230000005867 T cell response Effects 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000028172 protozoa infectious disease Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 description 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29678810P | 2010-01-20 | 2010-01-20 | |
| US61/296,788 | 2010-01-20 | ||
| PCT/US2011/021943 WO2011091181A1 (en) | 2010-01-20 | 2011-01-20 | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517331A JP2013517331A (ja) | 2013-05-16 |
| JP2013517331A5 true JP2013517331A5 (enExample) | 2014-03-06 |
| JP5947727B2 JP5947727B2 (ja) | 2016-07-06 |
Family
ID=44307213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550126A Expired - Fee Related JP5947727B2 (ja) | 2010-01-20 | 2011-01-20 | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US8846397B2 (enExample) |
| EP (1) | EP2525822B1 (enExample) |
| JP (1) | JP5947727B2 (enExample) |
| CA (1) | CA2787755A1 (enExample) |
| WO (1) | WO2011091181A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
| JP5837821B2 (ja) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
| CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| EP2525822B1 (en) | 2010-01-20 | 2017-05-10 | Merck Sharp & Dohme Corp. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| US20150174203A1 (en) * | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Ｆｃ領域含有ポリペプチドの精製を効率化するための方法 |
| JP7010491B2 (ja) | 2016-04-11 | 2022-01-26 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | ヒト化抗ｒａｇｅ抗体 |
| CA3047833A1 (en) * | 2016-12-22 | 2018-06-28 | Icahn School Of Medicine At Mount Sinai | Anti-lilrb3 antibodies and methods of use thereof |
| AU2019302454A1 (en) | 2018-07-09 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to ILT4 |
| JP7631203B2 (ja) * | 2019-01-18 | 2025-02-18 | ユニバーシティ ヘルス ネットワーク | Ｌｉｌｒｂ３結合分子とその使用 |
| CN114908164A (zh) * | 2022-03-07 | 2022-08-16 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | Ilt5在结直肠癌诊治中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61122292A (ja) | 1984-11-16 | 1986-06-10 | Teijin Ltd | 新規カルバサイクリン中間体の製法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69233701T2 (de) | 1991-03-18 | 2008-04-10 | New York University | Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DK0614984T4 (da) | 1993-03-05 | 2010-12-20 | Bayer Healthcare Llc | Humane monoklonale anti-TNF-alfa-antistoffer |
| US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
| US20060078564A1 (en) * | 2002-05-08 | 2006-04-13 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| CA2398251A1 (en) | 2000-01-25 | 2001-08-02 | Hyseq, Inc. | Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides |
| AU2001239955A1 (en) | 2000-02-28 | 2001-09-12 | Hyseq, Inc. | Novel macrophage nucleic acids and polypeptides |
| JP2004501624A (ja) * | 2000-06-28 | 2004-01-22 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用 |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| WO2003041650A2 (en) * | 2001-11-14 | 2003-05-22 | Immunex Corporation | Modulation of lir function to treat rheumatoid arthritis |
| WO2003051834A2 (en) | 2001-12-14 | 2003-06-26 | President And Fellows Of Harvard College | Immunocellular receptors related to neurological disorders |
| NZ543960A (en) | 2003-05-09 | 2008-11-28 | Univ Duke | CD20-specific antibodies and methods of employing same |
| CA2606576A1 (en) | 2005-05-20 | 2006-11-23 | Lonza Biologics Plc. | High-level expression of recombinant antibody in a mammalian host cell |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| SG163615A1 (en) | 2005-07-11 | 2010-08-30 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| WO2007092165A2 (en) | 2006-01-23 | 2007-08-16 | President And Fellows Of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
| TW200815470A (en) | 2006-03-30 | 2008-04-01 | Novartis Ag | Compositions and methods of use for antibodies of c-Met |
| EP2037961B1 (en) | 2006-06-14 | 2015-11-11 | MacroGenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| WO2008094176A2 (en) | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| KR20090082480A (ko) | 2006-11-14 | 2009-07-30 | 제넨테크, 인크. | 뉴런 재생의 조절인자 |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| US8715941B2 (en) | 2007-11-16 | 2014-05-06 | Arca Biopharma, Inc. | Antibodies to LRP6 |
| AU2008335245A1 (en) * | 2007-12-11 | 2009-06-18 | Genentech, Inc. | Modulators of neuronal regeneration |
| US20090285803A1 (en) * | 2008-05-13 | 2009-11-19 | Jasvinder Atwal | ANTI-PirB ANTIBODIES |
| CN102089327A (zh) | 2008-05-13 | 2011-06-08 | 健泰科生物技术公司 | 抗PirB抗体 |
| WO2010005519A1 (en) | 2008-06-30 | 2010-01-14 | University Of Pennsylvania | Fn14/trail fusion proteins |
| CA2739918A1 (en) * | 2008-10-07 | 2010-04-15 | Biovest International, Inc. | Methods for inducing a sustained immune response against a b-cell idiotype using autologous anti-idiotypic vaccines |
| CN102421913A (zh) | 2009-03-13 | 2012-04-18 | 宾夕法尼亚大学董事会 | Ox40/trail融合蛋白 |
| MX353186B (es) | 2009-09-03 | 2018-01-05 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
| EP2525822B1 (en) | 2010-01-20 | 2017-05-10 | Merck Sharp & Dohme Corp. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| CA2787783A1 (en) * | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
| WO2012061620A1 (en) | 2010-11-04 | 2012-05-10 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| AR086287A1 (es) | 2011-05-05 | 2013-12-04 | Baylor Res Inst | Composicion inmunoestimulante, metodo |
| US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
-
2011
- 2011-01-20 EP EP11735200.5A patent/EP2525822B1/en not_active Not-in-force
- 2011-01-20 CA CA2787755A patent/CA2787755A1/en not_active Abandoned
- 2011-01-20 US US13/574,391 patent/US8846397B2/en active Active
- 2011-01-20 JP JP2012550126A patent/JP5947727B2/ja not_active Expired - Fee Related
- 2011-01-20 WO PCT/US2011/021943 patent/WO2011091181A1/en not_active Ceased
-
2014
- 2014-08-19 US US14/462,596 patent/US9534051B2/en active Active
-
2016
- 2016-12-07 US US15/371,843 patent/US20170158765A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517331A5 (enExample) | ||
| Fend et al. | Immune checkpoint blockade, immunogenic chemotherapy or IFN-α blockade boost the local and abscopal effects of oncolytic virotherapy | |
| RU2711408C2 (ru) | Способы лечения рака с применением антагонистов pd-1 и pd-l1 в комбинации с лучевой терапией | |
| Paget et al. | Role of γδ T Cells in α-Galactosylceramide–Mediated Immunity | |
| Wachowska et al. | 5-Aza-2′-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy | |
| Sims | Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer | |
| AR086287A1 (es) | Composicion inmunoestimulante, metodo | |
| Yu et al. | Therapeutic dendritic cell vaccines engineered with antigen‐biomineralized Bi2S3 nanoparticles for personalized tumor radioimmunotherapy | |
| Younes et al. | Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity | |
| Nicolin et al. | Cellular immune response to a drug-treated L5178Y lymphoma subline | |
| KR102047323B1 (ko) | 자가 암 세포 백신 | |
| Fujinami et al. | Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model | |
| US10195267B2 (en) | Vaccination strategy | |
| JP2014516538A5 (enExample) | ||
| CN106166294A (zh) | 一种用于术前介入放疗治疗肿瘤的化合物 | |
| KR20190122717A (ko) | 면역 증강제, 면역치료 약학적 조성물 및 이의 제조 및 용도 | |
| Aricò et al. | Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis | |
| Kumar et al. | Improved protection against tuberculosis after boosting the BCG-primed mice with subunit Ag 85a delivered through intact skin with deformable vesicles | |
| JP2022534295A (ja) | ワクチン接種及び疾患治療法のための自己人工多能性幹細胞とのポックスウイルスの使用 | |
| Zhou | Compare among Three Immunotherapies Against Cancer: Vaccine Immunotherapy, Immune Checkpoint Blockade and Adoptive Immunotherapy | |
| Dorostkar et al. | Immunotherapeutic efficacy of a Lactobacillus casei lysate as an adjuvant combined with a heated-4T1 mammary carcinoma cell lysate in a murine model of breast cancer | |
| DeVault et al. | 753 InhibigenTM administration promotes aberrant T cell responses in cancer but may be beneficial for amelioration of autoimmune disease | |
| Manspeaker | Engineered Nanotechnology for the Delivery of Cancer Immunotherapies to Lymph Nodes to Modulate Anti-Tumor T Cell Immunity | |
| Paget et al. | Role of Natural Killer T Cells In Immunogenic Chemotherapy for Breast Cancer | |
| Fresnay et al. | Bone marrow vaccination: A novel approach to enhance antigen specific antitumor immunity |